Home / uPAR / Human uPAR Antibody

Human uPAR Antibody

Catalog #: MAB807
20 Citations 3 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB807-SP
MAB807-100
MAB807-500
Detection of uPAR in Human Blood Granulocytes by Flow Cytometry.
1 Image
Product Details
Citations (20)
FAQs
Supplemental Products
Reviews (3)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human uPAR Antibody Summary

Species Reactivity
Human
Specificity
Detects human uPAR in direct ELISAs and Western blots. When used in a sandwich ELISA in combination with the biotinylated anti-human uPAR detection antibody (Catalog # BAF807), no significant cross-reactivity was observed with recombinant mouse uPAR.
Source
Monoclonal Mouse IgG1 Clone # 62022
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
Recombinant Human uPAR (Catalog # 807-UK)
under non-reducing conditions only
Flow Cytometry
0.25 µg/106 cells
See below
Blockade of Receptor-ligand Interaction
In a functional ELISA, 0.5-1.5 µg/mL of this antibody will block 50% of the binding of 30 ng/mL of Recombinant Human uPAR (Catalog # 807-UK) to immobilized Recombinant Human u-Plasminogen Activator/Urokinase (Catalog # 1310-SE) coated at 500 ng/mL (100 µL/well). At 10 μg/mL, this antibody will block >90% of the binding.
 
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Human uPAR Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human uPAR Biotinylated Antibody (Catalog # BAF807)

Standard: Recombinant Human uPAR Protein (Catalog # 807-UK)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Flow Cytometry Detection of uPAR antibody in Human Blood Granulocytes antibody by Flow Cytometry. View Larger

Detection of uPAR in Human Blood Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with Mouse Anti-Human uPAR Monoclonal Antibody (Catalog # MAB807, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Loading...
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.

Background: uPAR

The urokinase-type Plasminogen Activator (uPA) is one of two activators that converts the extracellular zymogen plasminogen to plasmin, a serine protease that is involved in a variety of normal and pathological processes that require cell migration and/or tissue destruction. uPA is synthesized and released from cells as a
single-chain (sc) pro-enzyme with limited enzymatic activity and is converted to an active two-chain (tc) disulfide-linked active enzyme by plasmin and other specific proteinases. Both the scuPA and tcuPA bind with high-affinity to the cell surface via the glycosyl phosphatidylinositol-linked receptor uPAR which serves to localize the uPA proteolytic activity. The enzymatic activity of scuPA has also been shown to be enhanced by binding to uPAR. Independent of their proteolytic activity, the uPA/uPAR interaction also initiates signal transduction responses resulting in activation of protein tyrosine kinases, gene expression, cell adhesion, and chemotaxis. uPAR can interact with integrins to suppress normal integrin adhesive function and promote adhesion to vitronectin through a high affinity vitronectin binding site on uPAR. uPAR cDNA encodes a 335 amino acid (aa) residue precursor protein with a 22 aa residue signal peptide, five potential N-linked glycosylation sites and a
C‑terminal GPI-anchor site. An alternate spliced variant of uPAR encoding a secreted soluble form of uPAR also exists. Human and mouse uPAR share approximately 60% aa sequence identity and the receptor-ligand interaction is strictly species-specific.

References
  1. Dear, A.E. and R.L. Medcalf (1988) Eur. J. Biochemistry 252:185.
Long Name
Urokinase-type Plasminogen Activator Receptor
Entrez Gene IDs
5329 (Human); 18793 (Mouse); 102139334 (Cynomolgus Monkey)
Alternate Names
CD87 antigen; CD87; Monocyte activation antigen Mo3; plasminogen activator, urokinase receptor; PLAUR; uPAR; U-PAR; UPARurokinase plasminogen activator surface receptor; u-plasminogen activator receptor form 2; URKRMO3

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human uPAR Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

20 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Simultaneous stabilization of actin cytoskeleton in multiple nephron-specific cells protects the kidney from diverse injury
    Authors: K Mukherjee, C Gu, A Collins, M Mettlen, B Samelko, MM Altintas, YR Sudhini, X Wang, R Bouley, D Brown, BP Pedro, SL Bane, V Gupta, PT Brinkkoett, H Hagmann, J Reiser, S Sever
    Nature Communications, 2022-05-03;13(1):2422.
  2. New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice
    Authors: Thiruvengadam Arumugam, Defeng Deng, Laura Bover, Huamin Wang, Craig D. Logsdon, Vijaya Ramachandran
    Molecular Cancer Therapeutics
  3. Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation
    Authors: N McNamee, LR de la Fuen, MJ Santos-Mar, L O'Driscoll
    BMC Cancer, 2022-09-29;22(1):1023.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
    Authors: S Sharma, T Watanabe, T Nishimoto, T Takihara, L Mlakar, XX Nguyen, M Sanderson, Y Su, RA Chambers, C Feghali-Bo
    JCI Insight, 2021-12-22;6(24):.
    Species: Human
    Sample Types: Cell Fractions
    Applications: Immunoprecipitation, Western Blot
  5. Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells
    Authors: M van Veen, E Matas-Rico, K van de Wet, D Leyton-Pui, KM Kedziora, V De Lorenzi, Y Stijf-Bult, B van den Br, K Jalink, N Sidenius, A Perrakis, WH Moolenaar
    Elife, 2017-08-29;6(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. The periodontal pathogen Porphyromonas gingivalis preferentially interacts with oral epithelial cells in S phase of the cell cycle
    Authors: FB Al-Taweel, CW Douglas, SA Whawell
    Infect Immun, 2016-06-23;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Authors: Gilder A, Jones K, Hu J, Wang L, Chen C, Carter B, Gonias S
    J Biol Chem, 2015-04-02;290(24):14798-809.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  8. Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
    Authors: Kacsinta A, Rubenstein C, Sroka I, Pawar S, Gard J, Nagle R, Cress A
    Biochem Biophys Res Commun, 2014-10-22;454(2):335-40.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  9. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Authors: Huang J, Liu G, Zhang Y, Cui Z, Wang F, Liu X, Chu R, Zhao M
    BMC Med, 2014-05-20;12(0):81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  10. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
    Authors: Tersteeg C, de Maat S, De Meyer S, Smeets M, Barendrecht A, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot P, Maas C
    Circulation, 2014-01-21;129(12):1320-31.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  11. Activation of the plasma kallikrein-kinin system on human lung epithelial cells.
    Authors: Vergiliana JF, Asokananthan N, Stewart GA
    Biol. Chem., 2010-09-01;391(9):1067-77.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: Flow Cytometry, ICC, IHC-P
  12. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine.
    Authors: Hu H, Kwun J, Aizenstein BD, Knechtle SJ
    Transplantation, 2009-06-27;87(12):1814-20.
    Species: Human
    Sample Types: Urine
    Applications: Antibody Array Development
  13. AP-1-controlled hepatocyte growth factor activation promotes keratinocyte migration via CEACAM1 and urokinase plasminogen activator/urokinase plasminogen receptor.
    Authors: Schnickmann S, Camacho-Trullio D, Bissinger M, Eils R, Angel P, Schirmacher P, Szabowski A, Breuhahn K
    J. Invest. Dermatol., 2008-11-20;129(5):1140-8.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: Neutralization, Western Blot
  14. Development and validation of sandwich ELISA microarrays with minimal assay interference.
    Authors: Gonzalez RM, Seurynck-Servoss SL, Crowley SA
    J. Proteome Res., 2008-04-19;7(6):2406-14.
    Species: Human
    Sample Types: Serum
    Applications: ELISA Microarray Development
  15. Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.
    Authors: Brooks AM, Bates ME, Vrtis RF, Jarjour NN, Bertics PJ, Sedgwick JB
    Am. J. Respir. Cell Mol. Biol., 2006-05-25;35(4):503-11.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  16. LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion.
    Authors: Spijkers PP, da Costa Martins P, Westein E, Gahmberg CG, Zwaginga JJ, Lenting PJ
    Blood, 2004-08-24;105(1):170-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  17. Differences in integrin expression and signaling within human breast cancer cells
    Authors: Aliakbar Taherian, Xinlei Li, Yongqing Liu, Thomas A Haas
    BMC Cancer
  18. Variability in CKD Biomarker Studies: Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Kidney Disease Progression in the Chronic Kidney Disease in Children (CKiD) Study
    Authors: Alison G. Abraham, Yunwen Xu, Jennifer L. Roem, Jason H. Greenberg, Darcy K. Weidemann, Venkata S. Sabbisetti et al.
    Kidney Medicine
  19. Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA
    Authors: Huajiao Guo, Fuhao Wang, Yuwen Diao, Zhe Zhang, Qiuyan Chen, Chao‐Nan Qian et al.
    Molecular Carcinogenesis
  20. Macrophage-Dependent Cleavage of the Laminin Receptor alpha 6 beta 1 in Prostate Cancer
    Authors: Isis C. Sroka, Cynthia P. Sandoval, Harsharon Chopra, Jaime M. C. Gard, Sangita C. Pawar, Anne E. Cress
    Molecular Cancer Research

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human uPAR Antibody

Average Rating: 5 (Based on 3 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human uPAR Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human uPAR Antibody
By Anonymous on 05/27/2022
Application: WB Sample Tested: Cell Lysates Species: Human
Human uPAR Antibody
By Martin Torres on 09/24/2021
Application: WB Sample Tested: Serum Species: Human

The impact of prolactin treatments was used to assess human uPAR expression using western blot. Results were reliable, the intra-assay variation was low, and the obtained outcomes were in agreement with reported results from the literature. In the picture, the densitometric analysis from western blot is depicted, showing a control (without prolactin treatment), a pharmacological treatment using PRL treatments, a specific 16 kDa PRL treatment, and methotrexate as PRLR inhibitor.

Human uPAR Antibody
By Anonymous on 09/04/2021
Application: WB Sample Tested: Human Blood Granulocytes Species: Human